244 related articles for article (PubMed ID: 30958892)
1. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B; Morland B; Jiménez I; Frappaz D; Pearson ADJ; Vassal G; Maeda P; Kincaide J; Mueller U; Schlief S; Teufel M; Ploeger BA; Cleton A; Agostinho AC; Marshall LV
Eur J Cancer; 2021 Aug; 153():142-152. PubMed ID: 34157616
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM; Blobe GC; Strickler JH; Uronis HE; Zafar SY; Morse M; Dropkin E; Howard L; O'Neill M; Rushing CN; Niedzwiecki D; Watson H; Bolch E; Arrowood C; Liu Y; Nixon AB; Hurwitz HI
Cancer Chemother Pharmacol; 2019 Oct; 84(4):909-917. PubMed ID: 31444620
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Büchert M; Fasol U; Unger C; Krätzschmar J; Heinig R; Boix O; Christensen O
Clin Cancer Res; 2012 May; 18(9):2658-67. PubMed ID: 22421192
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
Sunakawa Y; Furuse J; Okusaka T; Ikeda M; Nagashima F; Ueno H; Mitsunaga S; Hashizume K; Ito Y; Sasaki Y
Invest New Drugs; 2014 Feb; 32(1):104-12. PubMed ID: 23553067
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
9. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer.
Kim ST; Kim TW; Kim KP; Kim TY; Han SW; Lee JY; Lim SH; Lee MY; Kim H; Park YS
Cancer Res Treat; 2015 Oct; 47(4):790-5. PubMed ID: 25672574
[TBL] [Abstract][Full Text] [Related]
17. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors.
Poklepovic AS; Gordon SW; Kothadia S; McGuire WP; Thacker LR; Deng X; Tombes MB; Shrader E; Hudson D; Bandyopadhyay D; Ryan AA; Kmieciak M; Smith S; Dent P
Anticancer Drugs; 2024 Jun; 35(5):450-458. PubMed ID: 38452059
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
